Abstract
Metastatic melanoma is one of the most intractable tumors, with all current regimens showing limited survival impact. Failure of most agents is attributed to development of therapy resistance. Accumulated evidence points to the apoptotic defect of melanoma cells and the surge of survival signals stimulated by cytotoxic drugs, as a way that tumors circumvent cytotoxic chemotherapy. An overview of inhibitors developed against these growth/survival factors, which are potential partners to be combined with systemic chemotherapy, will be discussed. The escape mechanism from molecular inhibitors also suggests a “vertical” or “horizontal” combination of molecularly targeted therapies. A better understanding of the interactions between simultaneously used regimens and of the rationale for combination therapy will provide new insights to improve survival and quality of life in patients with advanced melanoma.
Keywords: Melanoma, chemotherapy, drug resistance, targeted therapy, radiation, immunotherapy, dacarbazine, dartmouth regimen, biologics, tremelimumab, ipilimumab, BRAF inhibitor PLX4032, tumor cells, cancer therapy, chemotherapeutic agents
Current Molecular Medicine
Title: Resistance to Chemotherapy and Molecularly Targeted Therapies: Rationale for Combination Therapy in Malignant Melanoma
Volume: 11 Issue: 7
Author(s): S. Wu and R.K. Singh
Affiliation:
Keywords: Melanoma, chemotherapy, drug resistance, targeted therapy, radiation, immunotherapy, dacarbazine, dartmouth regimen, biologics, tremelimumab, ipilimumab, BRAF inhibitor PLX4032, tumor cells, cancer therapy, chemotherapeutic agents
Abstract: Metastatic melanoma is one of the most intractable tumors, with all current regimens showing limited survival impact. Failure of most agents is attributed to development of therapy resistance. Accumulated evidence points to the apoptotic defect of melanoma cells and the surge of survival signals stimulated by cytotoxic drugs, as a way that tumors circumvent cytotoxic chemotherapy. An overview of inhibitors developed against these growth/survival factors, which are potential partners to be combined with systemic chemotherapy, will be discussed. The escape mechanism from molecular inhibitors also suggests a “vertical” or “horizontal” combination of molecularly targeted therapies. A better understanding of the interactions between simultaneously used regimens and of the rationale for combination therapy will provide new insights to improve survival and quality of life in patients with advanced melanoma.
Export Options
About this article
Cite this article as:
Wu S. and Singh R.K., Resistance to Chemotherapy and Molecularly Targeted Therapies: Rationale for Combination Therapy in Malignant Melanoma, Current Molecular Medicine 2011; 11 (7) . https://dx.doi.org/10.2174/156652411800615153
DOI https://dx.doi.org/10.2174/156652411800615153 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulation of Cell Migration and Invasion by Specific Modules of uPA: Mechanistic Insights and Specific Inhibitors
Current Drug Targets Gold Nanoparticles; Potential Nanotheranostic Agent in Breast Cancer: A Comprehensive Review with Systematic Search Strategy
Current Drug Metabolism Synthetic Curcumin Analog UBS109 Inhibits the Growth of Head and Neck Squamous Cell Carcinoma Xenografts
Current Cancer Drug Targets Copper Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Recent Progress on the Discovery of NLRP3 Inhibitors and their Therapeutic Potential
Current Medicinal Chemistry Homeostasis and the Importance for a Balance Between AKT/mTOR Activity and Intracellular Signaling
Current Medicinal Chemistry Energetic Metabolic Roles in Pulmonary Arterial Hypertension and Right Ventricular Remodeling
Current Pharmaceutical Design Protein Targeting Constructs in Alpha Therapy
Current Radiopharmaceuticals The Faulty Perinatal Hormonal Imprinting as Functional Teratogen
Current Pediatric Reviews Blockade of Insulin-Like Growth Factor Type-1 Receptor with Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers
Current Drug Targets Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives
Anti-Cancer Agents in Medicinal Chemistry Extracellular HSP90: An Emerging Target for Cancer Therapy
Current Signal Transduction Therapy Skin Photoprotection by Green Tea: Antioxidant and Immunomodulatory Effects
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Understanding the Monoclonal Antibody Involvement in Targeting the Activation of Tumor Suppressor Genes
Current Topics in Medicinal Chemistry Proteasome Inhibitors in Cancer Therapy
Current Drug Targets IDO and Clinical Conditions Associated with Depressive Symptoms
Current Drug Metabolism Photochemical Reactions: Synthesis of Six-membered N-heterocycles
Current Organic Synthesis Oleanolic Acid Derived from Plants: Synthesis and Pharmacological Properties of A-ring Modified Derivatives
Letters in Drug Design & Discovery Nutraceuticals for Promoting Longevity
Current Nutraceuticals